Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

DNL593

Source date not recordedAnalyse record ↗

Brain-penetrant progranulin replacement protein in fully enrolled Phase 1/2 follow-up for GRN-related frontotemporal dementia.

Modality
intravenous blood-brain-barrier-crossing progranulin replacement protein
Availability (US)
Phase 1/2 study Active, not recruiting; enrollment complete
Biomarkers
treatment-emergent adverse events; cerebrospinal-fluid progranulin; neurofilament light; pharmacokinetics and pharmacodynamics
Hallmark targeted
lysosomal dysfunction, impaired autophagy, loss of proteostasis, neuroinflammation
Kind
investigational protein replacement therapy
Clinical trials
NCT05262023 — Phase 1/Phase 2, Active, not recruiting on January 15, 2026 registry update